<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://peptidenewsnetwork.com/articles/ai-designed-peptides-rfpeptides/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>AI-Designed Peptides: How RFpeptides Rewrote the First Step of Drug Discovery</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/amycretin-zenagamtide-glp1-amylin/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>Amycretin and the Quiet Return of Amylin</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/bpc-157-tb-500-research-peptides-evidence/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>&quot;Research Peptides&quot;: What the Evidence Actually Says</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/cagrisema-redefine-phase-3-results/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>CagriSema and the Power of a Pairing: The REDEFINE Results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/compounded-semaglutide-tirzepatide-fda-end/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>The End of the Compounding Era for GLP-1 Drugs</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/designed-proteins-snake-venom-antivenom/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>Designed Proteins Neutralize Snake Venom — and Hint at Antivenom Without the Horses</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/evoke-trial-semaglutide-alzheimers-design/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>Inside evoke and evoke+: How the Largest GLP-1 Dementia Trial Was Run</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/fda-bpc-157-peptide-compounding-hearing-2026/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>The Peptide Reckoning: The FDA&apos;s July 2026 Hearing on BPC-157</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/fda-glp1-direct-to-consumer-ad-crackdown/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>Washington Takes Aim at the Weight-Loss Ad</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/fda-wegovy-semaglutide-mash-approval/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>A Weight-Loss Drug, Approved for a Liver Disease</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/glp1-alzheimers-semaglutide-biomarkers/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>GLP-1 and the Aging Brain: A Negative Result Worth Reading Twice</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/glp1-direct-to-consumer-price-war/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>The Direct-to-Consumer Price War</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/glp1-gip-glucagon-amylin-explained/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>GLP-1, GIP, Glucagon, Amylin: The Gut-Hormone Alphabet</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/glp1-manufacturing-onshoring-lilly-novo/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>Building the Factory at Home</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/how-peptide-drugs-are-made/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>How a Peptide Drug Gets Made — and How AI Is Rewriting the First Step</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/novo-nordisk-reset-amycretin-strategy/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>Novo Nordisk&apos;s Year of Reset</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/oral-glp1-approvals-semaglutide-orforglipron/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>Two Oral GLP-1s, Two Very Different Molecules</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/orforglipron-attain-achieve-oral-glp1-trials/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>A Pill That Skips the Fasting Ritual: The Orforglipron Trials</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/pfizer-metsera-acquisition-obesity/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>Pfizer Wins Metsera — and a Platform</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/retatrutide-triumph-1-phase-3-results/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>Retatrutide Sets a New Ceiling: Inside TRIUMPH-1</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/semaglutide-mash-essence-trial-liver/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>What the Liver Told Us: Semaglutide, MASH, and the ESSENCE Trial</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/surpass-cvot-tirzepatide-dulaglutide-results/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>The First Incretin Head-to-Head on the Heart: SURPASS-CVOT</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/trumprx-glp1-pricing-medicare-deal/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>The Price of a Blockbuster, Renegotiated</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/what-is-a-peptide-explained/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>What Is a Peptide? The Molecule Behind the Headlines</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidenewsnetwork.com/articles/why-peptides-injected-pills-half-life/</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide News Network</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-12T00:00:00.000Z</news:publication_date>
      <news:title>Why Peptides Get Injected — and How the Pill Finally Happened</news:title>
    </news:news>
  </url>
</urlset>
